The National Institute for Health and Care Excellence2d
First-ever NHS treatment approved for advanced Hodgkin lymphoma
From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...
The National Institute for Health and Care Excellence3d
HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging ...
The National Institute for Health and Care Excellence2d
Record number of positive recommendations for blood cancer treatments
NICE has made 97 positive recommendations for blood cancer treatments over the last decade, five times more than in the previous ten years. 92% of blood cancer treatment recommendations since 2015 ...
National Institute for Health and Care Excellence7d
2 Information about blinatumomab
Blinatumomab (Blincyto, Amgen) is indicated for 'the treatment of adult patients with Philadelphia chromosome negative CD19-positive B-cell precursor leukaemia ALL in the consolidation phase'. The ...